[ad_1]
Moderna
the biotechnology company, was falling on Friday after a study of its new flu vaccine had mixed results.
Moderna (ticker: MRNA) said on Thursday that its experimental RNA-based influenza vaccine generated a strong immune response, but that it wasn’t proven that it was at least as effective as already-approved vaccines.
[ad_2]
Source link